These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31050100)

  • 1. The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
    Trossaert M; Graveleau J; Thiercelin-Legrand MF; Sigaud M; Guerrero F; Neel A; Fouassier M; Sailler L; Chauveau D; Ternisien C; Huart A; Gillet B; Hamidou M; Bene MC; Voisin S
    Haemophilia; 2019 May; 25(3):527-534. PubMed ID: 31050100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A.
    Mizrahi T; Doyon K; Dubé E; Bonnefoy A; Warner M; Cloutier S; Demers C; Castilloux JF; Rivard GE; St-Louis J
    Haemophilia; 2019 Mar; 25(2):252-257. PubMed ID: 30694571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of Acquired Hemophilia A after COVID-19 Infection.
    Marumo A; Sugihara H; Omori I; Morishita E
    J Nippon Med Sch; 2024 Jan; 90(6):474-479. PubMed ID: 36823120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
    Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
    Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
    Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort.
    Salaj P; Geierová V; Ivanová E; Loužil J; Pohlreichová V; Hrachovinová I; Dulíček P
    Haemophilia; 2020 Jul; 26(4):643-651. PubMed ID: 32590889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling.
    Mazurier C; Gaucher C; Jorieux S; Parquet-Gernez A; Goudemand M
    Br J Haematol; 1990 Nov; 76(3):372-9. PubMed ID: 2124499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.
    Tiede A; Hofbauer CJ; Werwitzke S; Knöbl P; Gottstein S; Scharf RE; Heinz J; Groß J; Holstein K; Dobbelstein C; Scheiflinger F; Koch A; Reipert BM
    Blood; 2016 May; 127(19):2289-97. PubMed ID: 26912467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.